AVI BioPharma (AVII) Misses Q3 Views by 1c
More News related to AVII
- AVI BioPharma (AVII) to Present Data for Duchenne Muscular Dystrophy Therapy at TREAT-NMD/NIH Conference
- AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference
- AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
- AVI BioPharma (AVII) Misses Q3 Views by 1c
- AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate Highlights
More News related to Earnings
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
AVI BioPharma (NASDAQ: AVII) reports Q3 loss of $0.08, versus the analyst estimate of ($0.07). Revenue for the quarter was $6.3 million, which compares to the estimate of $4.45 million.
Related Categories
EarningsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
